Avacta says AVA6103 candidate shows proof of mechanism in Phase 1
Avacta Group PLC said its AVA6103 drug candidate achieved proof of mechanism in a Phase 1 trial.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Avacta Group PLC said its AVA6103 drug candidate achieved proof of mechanism in a Phase 1 trial.